REMEGEN (09995): Huang Guobin appointed as independent non-executive director.
Rongchang Biology (09995) announced that Mr. Huang Guobin was appointed as an independent director of the second board of directors at the extraordinary general meeting.
REMEGEN (09995) announced that Mr. Huang Guobin has been appointed as an independent non-executive director of the second board of directors at the temporary shareholders' meeting. Mr. Huang's appointment is effective immediately after the temporary shareholders' meeting and will continue until the end of the second term of the board of directors. Mr. Huang has also been appointed as the chairman of the nomination committee and a member of the strategic committee, effective from his appointment as an independent non-executive director at the temporary shareholders' meeting until the end of the second term of the board of directors.
After the temporary shareholders' meeting, Dr. Ma Lan will no longer serve as an independent non-executive director, chairman of the nomination committee, and member of the strategic committee.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025